Catalyst Pharmaceutical Partners News (NASDAQ:CPRX)
| Latest Catalyst Pharmaceutical Partners News Headlines | | Date | Time | Source | | | 06/30/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphet
CORAL GABLES, Fla., June 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that it has begun... More...>> |
| 06/25/2008 | 11:23AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
CORAL GABLES, Fla., June 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced today that it is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its family of U.S. indexes on June 27, 2008, according to a preliminary list of additions posted on June... More...>> |
| 06/03/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
CORAL GABLES, Fla., June 3 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced the filing of a shelf... More...>> |
| 05/16/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results
Frank Greenway, M.D. Joins Catalyst's Scientific Advisory Board
CORAL GABLES, Fla., May 16 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended March 31, 2008. The Company also announced the addition of Frank Greenway, M.D. to Catalyst's... More...>> |
| 03/26/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine addiction
CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of... More...>> |
| 03/05/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
Patrick Kenny, Former Senior Clinical Research Associate at Kendle International, Inc., Joins Catalyst
CORAL GABLES, Fla., March 5 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced the appointment of Patrick Kenny as Director - Corporate Clinical Compliance. In this capacity... More...>> |
| 01/25/2008 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addi
- Additional Clinical Trial Sites To Be Added -
CORAL GABLES, Fla., Jan. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that... More...>> |
| 12/07/2007 | 6:25AM | PRNUS | Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
- Study Demonstrates Statistically Significant Efficacy vs. Placebo -
CORAL GABLES, Fla., Dec. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction... More...>> |
| 11/14/2007 | 5:51PM | PRNUS | Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
CORAL GABLES, Fla., Nov. 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended September 30, 2007.
Third Quarter 2007 Results
For the quarter ended September 30, 2007, the Company reported a net loss of $734,347 or $0.06 loss per basic... More...>> |
| 10/30/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners to Present at the Acumen Biofin 9th Annual Healthcare Conference
CORAL GABLES, Fla., Oct. 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that Patrick J. McEnany, President and Chief Executive... More...>> |
| 08/29/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners to Present at The Roth Capital Partners 2007 New York Conference
CORAL GABLES, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that Patrick... More...>> |
| 08/13/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners Reports Second Quarter 2007 Financial Results
- Initiates U.S. Phase II Clinical Trial for Cocaine Dependence
CORAL GABLES, Fla., Aug. 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended June 30, 2007.
Second Quarter 2007 Results
For the quarter ended June 30, 2007, the Company... More...>> |
| 07/10/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
CORAL GABLES, Fla., July 10 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind... More...>> |
| 05/14/2007 | 6:33PM | PRNUS | Catalyst Pharmaceutical Partners Reports First Quarter 2007 Financial Results
Company Successfully Completes Bioequivalence Study
CORAL GABLES, Fla., May 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the quarter ended March 31, 2007.
First Quarter 2007 Results
For the quarter ended March 31, 2007, the Company reported... More...>> |
| 05/09/2007 | 9:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Compa
CORAL GABLES, Fla., May 9 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced today positive initial, top-line results from a bioequivalence study demonstrating that CPP-109 (Catalyst's Vigabatrin Tablets) is bioavailable and bioequivalent to Sabril(R) Tablets, the version of vigabatrin... More...>> |
| 04/04/2007 | 8:03AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Names Vice President of Pharmaceutical Development and Project Management
Steven R. Miller, Ph.D., Former Executive Director of R&D Operations at Watson Laboratories, Joins Catalyst
CORAL GABLES, Fla., April 4 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced the appointment of Steven R. Miller, Ph.D. as Vice President of Pharmaceutical Development... More...>> |
| 04/02/2007 | 4:30PM | PRNUS | Catalyst Pharmaceutical Partners Reports Year-End 2006 Financial Results
- Start of U.S. Phase II clinical trial for Cocaine Addiction planned for second quarter of 2007
CORAL GABLES, Fla., April 2 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today reported financial results for the year ended December 31, 2006.
"During 2006, we achieved a number of important... More...>> |
| 02/14/2007 | 10:32AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Strengthens Scientific Advisory Board With Appointment of Richard A. Rawson, Ph.D.
Dr. Rawson is an Internationally Recognized Expert on Methamphetamine Dependence
CORAL GABLES, Fla., Feb. 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that it has appointed Dr. Richard Rawson to its Scientific Advisory Board, bringing the Board to seven members.
Dr... More...>> |
| 01/12/2007 | 9:10AM | PRNUS | Catalyst Pharmaceutical Partners, Inc. Adds Thomas Kosten, M.D. to Its Scientific Advisory Board
CORAL GABLES, Fla., Jan. 12 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today announced that it has added Dr. Thomas Kosten to its Scientific Advisory Board. Dr. Kosten is Waggoner Professor of Psychiatry and Neuroscience at Baylor College of Medicine and former Professor and Chief... More...>> |
| 01/03/2007 | 8:55AM | PRNUS | Catalyst Pharmaceutical Partners Provides an Update on its Clinical Development Plans for CPP-109
Catalyst to conduct two simultaneous U.S. Phase II clinical trials evaluating the use of CPP-109 in treating cocaine addiction and methamphetamine addiction
CORAL GABLES, Fla., Jan. 3 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) today provided an update on its clinical development plans... More...>> |
|
|
|